KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Receivables (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Change in Receivables for 16 consecutive years, with -$184.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 409.62% year-over-year to -$184.2 million, compared with a TTM value of $360.0 million through Dec 2025, up 315.9%, and an annual FY2025 reading of $360.0 million, up 315.9% over the prior year.
  • Change in Receivables was -$184.2 million for Q4 2025 at Alnylam Pharmaceuticals, down from $399.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $399.9 million in Q3 2025 and bottomed at -$184.2 million in Q4 2025.
  • Average Change in Receivables over 5 years is $34.1 million, with a median of $9.1 million recorded in 2021.
  • The sharpest move saw Change in Receivables tumbled 470.68% in 2022, then surged 1913.17% in 2025.
  • Year by year, Change in Receivables stood at $59.4 million in 2021, then fell by 10.4% to $53.3 million in 2022, then crashed by 107.26% to -$3.9 million in 2023, then soared by 1638.07% to $59.5 million in 2024, then plummeted by 409.62% to -$184.2 million in 2025.
  • Business Quant data shows Change in Receivables for ALNY at -$184.2 million in Q4 2025, $399.9 million in Q3 2025, and $136.9 million in Q2 2025.